Suzhou‑based Alphamab reported Phase 3 results showing its HER2 bispecific antibody anbenitamab (KN‑026) combined with chemotherapy reduced disease progression risk by about 75% in previously treated HER2‑positive gastric or gastroesophageal junction cancer patients. The randomized, double‑blind KC‑Wise trial met its primary endpoint, positioning KN‑026 plus chemo as a potential new standard for patients who failed first‑line trastuzumab‑containing regimens. The data, published in Annals of Oncology, come from a global multicenter study and mark a major late‑stage win for Alphamab. If regulators and payers accept the findings, the bispecific could shift the post‑trastuzumab treatment landscape in gastric cancer and draw attention from Big Pharma pursuing next‑generation HER2 modalities.